Announcement on Voluntary Disclosure of Completion of First Subject Enrollment in the Phase III Clinical Trial of T-Bren for Injection (HER2 ADC) for First-line HER2-positive Recurrent or Metastatic Breast Cancer

Announcement on Voluntary Disclosure of Completion of First Subject Enrollment in the Phase III Clinical Trial of T-Bren for Injection (HER2 ADC) for First-line HER2-positive Recurrent or Metastatic Breast Cancer

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment